Real-world outcomes associated with new cancer medicines approved by the Food and Drug Administration and European Medicines Agency: A retrospective cohort study

PURPOSE: Real-World Data (RWD) studies are increasingly used to support regulatory approvals, reimbursement decisions, and changes in clinical practice for novel cancer drugs. However, few studies have systematically appraised their quality or compared outcomes to pivotal trials. METHODS: All RWD st...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyle, Jemma M., Hegarty, Gemma, Frampton, Christopher, Harvey-Jones, Elizabeth, Dodkins, Joanna, Beyer, Katharina, George, Gincy, Sullivan, Richard, Booth, Christopher, Aggarwal, Ajay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science Ltd 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442759/
https://www.ncbi.nlm.nih.gov/pubmed/34371443
http://dx.doi.org/10.1016/j.ejca.2021.07.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442759/
https://www.ncbi.nlm.nih.gov/pubmed/34371443
http://dx.doi.org/10.1016/j.ejca.2021.07.001

Ejemplares similares